Back to Results

Cencora Inc (COR)

Cencora, Inc. is a common stock listing on the NYSE for a healthcare company focused on sourcing and distributing pharmaceutical products in the United States and abroad. Through its U.S. Healthcare Solutions segment, the company supplies generic and injectable medicines, over-the-counter healthcare products, home healthcare supplies and equipment, blood products, vaccines, and other specialty pharmaceuticals, while also providing pharmacy management, staffing, consulting, packaging, software, clinical trial support, commercialization services, and related data analytics. Its International Healthcare Solutions segment supports pharmaceutical wholesale and commercialization activities outside the United States and offers specialty transportation and logistics services for the biopharmaceutical industry. Formerly known as AmerisourceBergen Corporation, the company adopted the Cencora name in August 2023 and was founded in 1871. It is headquartered in Conshohocken, Pennsylvania.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-COR
$368.50
19.3% Upside
Undervalued
$369.31
19.6% Upside
Undervalued
Great
0.8%
November 11, 2026
22.5x
19.4x
0.2x
58.924 B
70.88 B
19.6%
94.5%
6.2
17.8%
154.7%
Valuation • Fair Value

Cencora Inc (NYSE-COR) Fair Value by Valuation Model

Review the available estimates for Cencora Inc (NYSE-COR), including DCF Fair Value, Ben Graham Formula Value, DDM Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$368.50

Estimated upside of 19.3% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$390.25

Discounted cash flow valuation reference.

Ben Graham Formula Value

$152.62

Classic Ben Graham valuation formula reference.

DDM Fair Value

$455.85

Dividend discount model valuation reference.

EPV Fair Value

$183.32

Earnings power value estimate.

Comps Fair Value

$348.51

Comparable-company valuation reference.

Analyst Price Target

$369.31

Analysts imply upside of 19.6%.

How to read these valuation models

Use the 8 available valuation references for Cencora Inc (NYSE-COR) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Cencora Inc (NYSE-COR)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

332.8 B

Current operating scale indicator.

Revenue Forecast

337.2 B

Forward revenue estimate.

EBITDA

5.546 B

Current operating profitability reference.

EBITDA Forecast

5.371 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Cencora Inc (NYSE-COR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cencora Inc (NYSE-COR)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.67

No elevated caution signal from this screen.

Altman Z-Score

6.2

Relatively strong balance-sheet zone.

FCF / Net Income

154.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cencora Inc (NYSE-COR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cencora Inc (NYSE-COR)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

54

Dividend Yield

0.8%

Current income yield reference.

Payout Ratio

17.8%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Cencora Inc (NYSE-COR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cencora Inc (NYSE-COR) Stock Forecast & Technical Outlook

Review Cencora Inc (NYSE-COR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Cencora Inc (NYSE-COR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Cencora Inc (NYSE-COR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Cencora Inc (NYSE-COR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Cencora Inc (NYSE-COR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Cencora Inc (NYSE-COR) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cencora Inc (NYSE-COR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Cencora Inc (NYSE-COR) has a Buy consensus, with 8 buy, 4 hold and 0 sell recommendations in the current data set.

Buy 8
Hold 4
Sell 0
FAQ • Fast Investor Answers

Cencora Inc (NYSE-COR) Stock FAQ

Data-supported answers about Cencora Inc (NYSE-COR), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$368.50
Estimated upside 19.3%
Valuation Rating
Undervalued
Estimated upside of 19.3%
Analyst Target
$369.31
Implied upside 19.6%
Financial Health
Great
Current financial-health read

The current fair value estimate for Cencora Inc (NYSE-COR) is $368.50. This implies an estimated upside of 19.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 19.3% versus the current market price.

The available analyst price target for Cencora Inc (NYSE-COR) is $369.31. The analyst target implies estimated upside of 19.6%.

The current financial health read for Cencora Inc (NYSE-COR) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cencora Inc (NYSE-COR) is November 11, 2026.

Based on the current data, dividend yield is 0.8%.

The current P/E ratio listed for Cencora Inc (NYSE-COR) is 22.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Cencora Inc is 58.924 B.

The current enterprise value listed for Cencora Inc is 70.88 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cencora Inc is NYSE-COR, and the stock is listed on NYSE.

Cencora Inc (NYSE-COR) is listed on NYSE.

The current debt-to-total-capital ratio listed for Cencora Inc is 19.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cencora Inc is 94.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Providers & Services Stocks View more on NYSE

Comparable companies from the same industry, limited to one security per issuer.

UNH NYSE Unitedhealth Group Fair Value Fair Market Cap 338.3 B
CVS NYSE CVS Health Corp Fair Value Undervalued Market Cap 113.6 B
MCK NYSE McKesson Corporation Fair Value Undervalued Market Cap 102 B
HCA NYSE HCA Holdings Inc Fair Value Fair Market Cap 92.6 B
ELV NYSE Elevance Health Inc Fair Value Fair Market Cap 89.122 B
CI NYSE Cigna Corp Fair Value Bargain Market Cap 72.74 B
CAH NYSE Cardinal Health Inc Fair Value Fair Market Cap 52.418 B
HUM NYSE Humana Inc Fair Value Fair Market Cap 46.377 B
CNC NYSE Centene Corp Fair Value Fair Market Cap 32.164 B
DGX NYSE Quest Diagnostics Incorporated Fair Value Fair Market Cap 27.202 B
LH NYSE Labcorp Holdings Inc Fair Value Fair Market Cap 26.01 B
GH NASDAQ Guardant Health Inc Fair Value Overvalued Market Cap 24.072 B
THC NYSE Tenet Healthcare Corporation Fair Value Fair Market Cap 21.095 B
EHC NYSE Encompass Health Corp Fair Value Fair Market Cap 12.011 B
BTSG NASDAQ Brightspring Health Services Inc Fair Value Fair Market Cap 11.838 B
FMS NYSE Fresenius Medical Care Corporation Fair Value Undervalued Market Cap 11.778 B
DVA NYSE DaVita HealthCare Partners Inc Fair Value Fair Market Cap 11.725 B
MOH NYSE Molina Healthcare Inc Fair Value Undervalued Market Cap 10.459 B
UHS NYSE Universal Health Services Inc Fair Value Undervalued Market Cap 10.413 B
ENSG NASDAQ The Ensign Group Inc Fair Value Fair Market Cap 10.056 B